Innoviva (INVA) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Innoviva (INVA) over the past year, gaining 55.4% versus a gain of 20.1%. Over five years, INVA leads with a +25.6% price change compared with -31.6% for PCRX. Innoviva is the larger company by market cap ($1.51 billion vs $1.45 billion), about 1.0 times the size.
On valuation, Innoviva trades at a lower forward P/E (9.4x vs 10.5x for Pacira BioSciences).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INVA | PCRX |
|---|---|---|
| Share price | $20.87 | $36.39 |
| Market cap | $1.51B | $1.45B |
| 1-day change | -0.90% | +44.40% |
| YTD return | +4.40% | +40.61% |
| 1-year return | +20.15% | +55.45% |
| 5-year return | +25.65% | -31.60% |
| P/E ratio (TTM) | 4.88 | 103.97 |
| Forward P/E | 9.44 | 10.52 |
| EPS (TTM) | $4.28 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.15 | $36.46 |
| 52-week low | $16.52 | $18.80 |
| Distance from 52-week high | -17.02% | -0.19% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +67.70% | -17.26% |
| Average volume | 819.03K | 1.03M |
| Shares outstanding | 72.25M | 39.86M |
| Employees | 159 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed INVA by 35.3 percentage points over the past year.
- Pacira BioSciences trades at a higher earnings multiple (104.0x vs 4.9x trailing P/E).
About Innoviva
INVA stock →Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
INVA vs PCRX FAQ
Which is bigger, Innoviva or Pacira BioSciences?
Innoviva (INVA) is larger, with a market capitalization of $1.51B compared with $1.45B for Pacira BioSciences (PCRX).
Which stock has performed better over the past year, INVA or PCRX?
PCRX returned +55.45% over the past 12 months, compared with +20.15% for INVA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, INVA or PCRX?
INVA has the lower trailing P/E at 4.9, versus 104.0 for PCRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Innoviva and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.